<?xml version='1.0' encoding='utf-8'?>
<document id="18647303"><sentence text="Maraviroc: in vitro assessment of drug-drug interaction potential."><entity charOffset="0-9" id="DDI-PubMed.18647303.s1.e0" text="Maraviroc" /></sentence><sentence text="To characterize the cytochrome P450 enzyme(s) responsible for the N-dealkylation of maraviroc in vitro, and predict the extent of clinical drug-drug interactions (DDIs)"><entity charOffset="84-93" id="DDI-PubMed.18647303.s2.e0" text="maraviroc" /></sentence><sentence text="" /><sentence text="Human liver and recombinant CYP microsomes were used to identify the CYP enzyme responsible for maraviroc N-dealkylation" /><sentence text=" Studies comprised enzyme kinetics and evaluation of the effects of specific CYP inhibitors" /><sentence text=" In vitro data were then used as inputs for simulation of DDIs with ketoconazole, ritonavir, saquinavir and atazanvir, using the Simcyptrade mark population-based absorption, distribution, metabolism and elimination (ADME) simulator"><entity charOffset="68-80" id="DDI-PubMed.18647303.s6.e0" text="ketoconazole" /><entity charOffset="82-91" id="DDI-PubMed.18647303.s6.e1" text="ritonavir" /><entity charOffset="93-103" id="DDI-PubMed.18647303.s6.e2" text="saquinavir" /><entity charOffset="108-117" id="DDI-PubMed.18647303.s6.e3" text="atazanvir" /><entity charOffset="129-140" id="DDI-PubMed.18647303.s6.e4" text="Simcyptrade" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e0" e2="DDI-PubMed.18647303.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e0" e2="DDI-PubMed.18647303.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e0" e2="DDI-PubMed.18647303.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e0" e2="DDI-PubMed.18647303.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e0" e2="DDI-PubMed.18647303.s6.e4" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e1" e2="DDI-PubMed.18647303.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e1" e2="DDI-PubMed.18647303.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e1" e2="DDI-PubMed.18647303.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e1" e2="DDI-PubMed.18647303.s6.e4" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e2" e2="DDI-PubMed.18647303.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e2" e2="DDI-PubMed.18647303.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e2" e2="DDI-PubMed.18647303.s6.e4" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e3" e2="DDI-PubMed.18647303.s6.e3" /><pair ddi="false" e1="DDI-PubMed.18647303.s6.e3" e2="DDI-PubMed.18647303.s6.e4" /></sentence><sentence text=" Study designs for simulations mirrored those actually used in the clinic" /><sentence text="" /><sentence text="Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0"><entity charOffset="0-9" id="DDI-PubMed.18647303.s9.e0" text="Maraviroc" /></sentence><sentence text="45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor)"><entity charOffset="72-84" id="DDI-PubMed.18647303.s10.e0" text="ketoconazole" /></sentence><sentence text=" In a panel of recombinant CYP enzymes, CYP3A4 was identified as the major CYP responsible for maraviroc metabolism"><entity charOffset="95-104" id="DDI-PubMed.18647303.s11.e0" text="maraviroc" /></sentence><sentence text=" Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1)" /><sentence text=" Simulations therefore focused on the effect of CYP3A4 inhibitors on maraviroc pharmacokinetics"><entity charOffset="69-78" id="DDI-PubMed.18647303.s13.e0" text="maraviroc" /></sentence><sentence text=" The simulated median AUC ratios were in good agreement with observed clinical changes (within twofold in all cases), although, in general, there was a trend for overprediction in the magnitude of the DDI" /><sentence text="" /><sentence text="Maraviroc is a substrate for CYP3A4, and exposure will therefore be modulated by CYP3A4 inhibitors"><entity charOffset="0-9" id="DDI-PubMed.18647303.s16.e0" text="Maraviroc" /></sentence><sentence text=" Simcyptrade mark has successfully simulated the extent of clinical interactions with CYP3A4 inhibitors, further validating this software as a good predictor of CYP-based DDIs" /><sentence text="" /></document>